Literature DB >> 29235260

Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis.

Tamas Dinya1, Tamas Tornai2, Zsuzsanna Vitalis2, Istvan Tornai2, Boglárka Balogh2, David Tornai3, Peter Antal-Szalmas3, Andrea Sumegi4, Hajnalka Andrikovics5, Andras Bors5, Attila Tordai6, Maria Papp2.   

Abstract

BACKGROUND & AIMS: Pattern recognition receptors (PRRs) have a key role in the innate host defense. Functional polymorphisms of various PRRs have been established to contribute to an increased susceptibility to spontaneous bacterial peritonitis (SBP). Their role in the development of cirrhosis-associated bacterial infections (BI), beyond SBP or progressive disease course related to pathological bacterial translocation (BT) remains unknown.
METHODS: Three hundred and forty-nine patients with cirrhosis were genotyped for common NOD2 (R702W, G908R and L1007PfsinsC), TLR2 (-16934T>A), and TLR4 (D299G) variants. Incidence of BIs, decompensating events and liver-related death were assessed in a 5-year follow-up observational study. Pathological BT was assessed based on the presence of antimicrobial antibodies or lipopolysaccharide-binding protein (LBP) level.
RESULTS: In patients with ascites (n = 88) only NOD2 gene variants were associated with an increased cumulative probability of SBP (76.9% ± 19.9%) compared to wild-type (30.9% ± 6.9%, PLogRank  = .047). Individual or combined PRR genetic profiles were associated with the risk of non-SBP type BI. Advanced disease stage (HR [95% CI]: 2.11 [1.38-3.25]) and prior history of a BI episode (HR: 2.42 [1.58-3.72]) were the major clinical risk factors of a subsequent BI. The risk of a non-SBP type BI in patients with advanced disease and a prior BI was even higher (HR: 4.74 [2.68-8.39]). The frequency of antimicrobial antibodies and LBP levels did not differ between various PRR genotypes. Correspondingly, PRR genetic profile was not able to predict the long-term disease course.
CONCLUSIONS: In cirrhosis, functional polymorphisms of PRRs did not improve the identification of patients with high risk of BI beyond SBP or progressive diseases course.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bacterial infection; cirrhosis; compliations; genetic polymorphisms; mortality; pattern recognition receptors

Mesh:

Substances:

Year:  2018        PMID: 29235260     DOI: 10.1111/liv.13664

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Are Pattern Recognition Receptors Associated with Hepatocellular Carcinoma?

Authors:  Ramazan Dertli; Mehmet Asil; Murat Bıyık; Ahmet Karakarcayıldız; Muharrem Keskin; Yusuf Kayar; Müşerref Başdemirci; Hüseyin Ataseven
Journal:  Turk J Gastroenterol       Date:  2021-07       Impact factor: 1.852

2.  Diabetes does not increase infection risk or mortality following an infection in patients with cirrhosis and ascites.

Authors:  Lars Bossen; Gitte A Dam; Hendrik Vilstrup; Hugh Watson; Peter Jepsen
Journal:  JHEP Rep       Date:  2019-08-08

3.  Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection.

Authors:  Jelte J Schaapman; Àlex Amoros; Johan J van der Reijden; Wim Laleman; Stefan Zeuzem; Rafael Bañares; Rajiv Jalan; Vicente Arroyo; Joan Clària; Hein W Verspaget; Minneke J Coenraad
Journal:  Liver Int       Date:  2020-02-16       Impact factor: 5.828

4.  Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma-A Single-Center Study.

Authors:  Theodoros Androutsakos; Athanasios-Dimitrios Bakasis; Abraham Pouliakis; Maria Gazouli; Christos Vallilas; Gregorios Hatzis
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

5.  Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis.

Authors:  Matthias Christian Reichert; Cristina Ripoll; Markus Casper; Robin Greinert; Edith Vandieken; Frank Grünhage; Beate Appenrodt; Alexander Zipprich; Frank Lammert
Journal:  Clin Transl Gastroenterol       Date:  2019-01       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.